Press releases

Press releases

19 November 2015  - Paris (France)

Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

29 October 2015  - Paris (France)

Ipsen: sales in the 3rd quarter and first nine months of 2015

28 October 2015  - Paris (France)

Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories

26 October 2015  - Paris (France)

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

22 October 2015  - Paris (France)

Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy

19 October 2015  - Paris (France)

Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

01 October 2015  - Paris (France)

Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen

01 October 2015  - Paris (France)

Ipsen announces release of an additional batch of Increlex® in the U.S.

29 September 2015  - Paris (France)

Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.

31 August 2015  - Paris (France)

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

Updated on 31 July 2015